Ben+Josef E., Porter A.T.
Radioisotopes in the treatment of bone metastases // Ann.
Med. — 1997 — V. 29(1). — P. 31 35.
Berenson J.R., Lipton A.
Use of bisphosphonates in patients with metastatic bone dis
ease // Oncology (Huntingt) — 1998. — V. 12(11). — P.1573 1581.
Berenson J.R., Lipton A.
Bisphosphonates in the treatment of malignant bone disease
// Annu. Rev. Med. — 1999. — V. 50. — P. 237 248.
Bergh J., Bonneterre J., Illiger H.J.,
è ñîàâò. Vorozole (Rivizor) versus aminog
lutethimide (AG) in the treatment of postmenopausal breast cancer relapsing after tamox
ifen // Pro.c Annu. Meet. Am. Soc. Clin. Oncol. — 1997. — V. 16. — P. 543a. Abstract.
Berle P., Voight K.
Evidens of plasma prolactin levels in patients with breast cancer
// Amer. J. Obstet. and Gynecol. — 1972. — V. 114. — P. 1101 1107.
Berna L., Carrio I., Alonso C.
Bone pain palliation with strontium 89 in breast can
cer patients with bone metastases and refractory bone pain // Eur. J. Nucl. Med. — 1995. —
V. 22(10). — P. 1101 1104.
Berning W., Freyschmidt J., Ostertag H.
Percutaneous bone biopsy. Critical analysis
of 153 patients // Unfallchirurg. — 1993. — V. 96(1). — P. 34 38.
Berruti A., Torta M., Piovesan À.
Biochemical picture of bone metabolism in breast
cancer patients with bone metastases // Anticancer Res. — 1995. — V.15 (6B). —
P. 2871 2875.
Berruti A., Piovesan A., Torta M., Raucci C.A., Gorzegno G., Paccotti P., Dogliotti L.,
Angeli A.
Biochemical evaluation of bone turnover in cancer patients with bone metastases:
relationship with radiograph appearances and disease extension // Br. J. Cancer. — 1996. —
V. 73(12). — P. 1581 1587.
Berruti A., Dogliotti L., Gorzegno G., Torta M., Tampellini M., Tucci M., Cerutti S.,
Frezet M.M., Stivanello M., Sacchetto G., Angeli A.
Differential patterns of bone turnover in
relation to bone pain and disease extent in bone in cancer patients with skeletal metastases
[see comments] // Clin. Chem. — 1999. — V. 45(8 Pt. 1). — P. 1240 1247.
Bertolini D.R., Nedwin G.E., Brown T.S., Smith D.D., Mundy G.R.
Stimulation of
bone resorption and inhibition of bone formation in vitro by human tumor necrosis factors
// Nature. — 1986. — V. 319. — P. 576 578.
Biermann W.A., Cantor R.I., Fellin F.M., Jakobowski J., Hopkins L., Newbold R.C.
An evaluation of the potential cost reductions resulting from the use of clodronate in the
treatment of metaststic carcinoma of the breast // Bone. — 1991. — V. 12. — P. 37 42.
Bishop H.M., Blamey R.W., Morris A.H., Rose D.H., Preston B., Lane J., Doyle P.J.
Bone scanning: its lack of value in the follow up of patients breast cancer // Br. J. Surg. —
1979. — V. 66. — P. 752 754.
Bitran J.D., Bekderman C., Desser R.K.
The predictive value of serial bone scans in
assessing response to chemotherapy in advanced breast cancer // Cancer. — 1980. —V. 45. —
P. 1562 1568.
Black P.
Spinal metastases. Current status and recommended guidelines for manag
ment. Neurosurg. — 1979. — V. 5. — P. 726 746.
Blackledge G.R.P., Latief T., Mound J.J., Spooner D., Morrison M.
Phase II evalution
of megestrol acetat in previously treated patients with advansced breast canxer: relationship
of response to previous treatment // Eur. J. Cancer Clin. Oncol. — 1986. — V. 22. —
P.1091 1094.
Blamey R.W., Campbell F.C., Nicholson R.L., Griffiths K.
Oestrogen receptor status
and sites of metastases in breast cancer // 3 rd EORTC Breast Cancer Working Conf.,
Abstract IV, VI. — 1983. — P. 26.
216
Êîñòíûå ìåòàñòàçû ðàêà ìîëî÷íîé æåëåçû
